William Steadman Kiger, III, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Boron Neutron Capture Therapy | 21 | 2012 | 50 | 2.450 |
Why?
|
| Radiometry | 10 | 2009 | 813 | 0.840 |
Why?
|
| Boron | 8 | 2008 | 37 | 0.780 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 11 | 2009 | 1660 | 0.600 |
Why?
|
| Linear Energy Transfer | 2 | 2009 | 152 | 0.570 |
Why?
|
| Boron Compounds | 8 | 2012 | 180 | 0.530 |
Why?
|
| Neutrons | 5 | 2007 | 77 | 0.430 |
Why?
|
| Radiotherapy Dosage | 9 | 2011 | 2897 | 0.410 |
Why?
|
| Autoradiography | 3 | 2009 | 730 | 0.390 |
Why?
|
| Glioblastoma | 9 | 2009 | 3482 | 0.380 |
Why?
|
| Fructose | 2 | 2004 | 287 | 0.370 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2009 | 228 | 0.320 |
Why?
|
| Phenylalanine | 4 | 2008 | 365 | 0.290 |
Why?
|
| Brain Neoplasms | 10 | 2009 | 8985 | 0.250 |
Why?
|
| Biological Assay | 1 | 2007 | 630 | 0.230 |
Why?
|
| Models, Biological | 5 | 2012 | 9468 | 0.190 |
Why?
|
| Monte Carlo Method | 6 | 2009 | 1257 | 0.190 |
Why?
|
| Cell Survival | 2 | 2009 | 5797 | 0.180 |
Why?
|
| Mouth Mucosa | 1 | 2002 | 426 | 0.160 |
Why?
|
| Phantoms, Imaging | 9 | 2008 | 2512 | 0.120 |
Why?
|
| Neutron Capture Therapy | 2 | 2002 | 6 | 0.100 |
Why?
|
| Brachytherapy | 2 | 2008 | 1238 | 0.090 |
Why?
|
| Androgen Antagonists | 2 | 2008 | 1442 | 0.080 |
Why?
|
| Relative Biological Effectiveness | 2 | 2007 | 312 | 0.080 |
Why?
|
| Dysuria | 1 | 2007 | 6 | 0.080 |
Why?
|
| Skin | 1 | 2002 | 4466 | 0.080 |
Why?
|
| Tosyl Compounds | 1 | 2008 | 112 | 0.070 |
Why?
|
| Fast Neutrons | 2 | 2004 | 18 | 0.070 |
Why?
|
| Goserelin | 1 | 2008 | 127 | 0.070 |
Why?
|
| Filtration | 1 | 2007 | 229 | 0.070 |
Why?
|
| Leuprolide | 1 | 2008 | 315 | 0.070 |
Why?
|
| Melanoma | 6 | 2004 | 5697 | 0.070 |
Why?
|
| Anilides | 1 | 2008 | 409 | 0.060 |
Why?
|
| Equipment Failure Analysis | 1 | 2007 | 848 | 0.060 |
Why?
|
| Computer Simulation | 2 | 2009 | 6218 | 0.060 |
Why?
|
| Cranial Irradiation | 1 | 2007 | 391 | 0.060 |
Why?
|
| Least-Squares Analysis | 1 | 2004 | 369 | 0.060 |
Why?
|
| Radiation Pneumonitis | 1 | 2004 | 102 | 0.060 |
Why?
|
| Lithium | 1 | 2007 | 596 | 0.060 |
Why?
|
| Immobilization | 1 | 2004 | 230 | 0.060 |
Why?
|
| Radiobiology | 1 | 2003 | 89 | 0.050 |
Why?
|
| Health Physics | 1 | 2022 | 30 | 0.050 |
Why?
|
| Nitriles | 1 | 2008 | 956 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2022 | 5870 | 0.050 |
Why?
|
| Equipment Design | 2 | 2007 | 3520 | 0.050 |
Why?
|
| Microchemistry | 1 | 2002 | 55 | 0.050 |
Why?
|
| Half-Life | 1 | 2003 | 652 | 0.050 |
Why?
|
| Internationality | 1 | 2007 | 1004 | 0.050 |
Why?
|
| International Cooperation | 2 | 2005 | 1433 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2003 | 877 | 0.040 |
Why?
|
| Radioisotopes | 1 | 2002 | 495 | 0.040 |
Why?
|
| Posture | 1 | 2004 | 953 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2009 | 2907 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2008 | 881 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2008 | 1529 | 0.040 |
Why?
|
| Accreditation | 1 | 2022 | 477 | 0.040 |
Why?
|
| Prostate | 1 | 2007 | 1793 | 0.040 |
Why?
|
| Isotopes | 2 | 2008 | 125 | 0.040 |
Why?
|
| Tongue | 1 | 2002 | 404 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2007 | 1957 | 0.040 |
Why?
|
| Radiography | 1 | 2009 | 6965 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2012 | 2882 | 0.040 |
Why?
|
| Lung | 2 | 2008 | 9994 | 0.040 |
Why?
|
| Humans | 23 | 2022 | 760613 | 0.040 |
Why?
|
| Algorithms | 3 | 2009 | 13982 | 0.040 |
Why?
|
| Health Facilities | 1 | 2022 | 578 | 0.040 |
Why?
|
| Glioma | 1 | 2012 | 3420 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2008 | 14661 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2001 | 2235 | 0.030 |
Why?
|
| Brain | 5 | 2009 | 26951 | 0.030 |
Why?
|
| Rats, Inbred F344 | 2 | 2008 | 825 | 0.030 |
Why?
|
| Reproducibility of Results | 3 | 2008 | 20080 | 0.030 |
Why?
|
| Prostatic Neoplasms | 2 | 2008 | 11345 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2012 | 9278 | 0.030 |
Why?
|
| Rats | 3 | 2008 | 23709 | 0.030 |
Why?
|
| Skin Neoplasms | 2 | 2003 | 5799 | 0.030 |
Why?
|
| Biophysical Phenomena | 2 | 2005 | 320 | 0.020 |
Why?
|
| Biophysics | 2 | 2005 | 380 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2003 | 3562 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2022 | 2363 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 16932 | 0.020 |
Why?
|
| Respiration | 2 | 2008 | 1654 | 0.020 |
Why?
|
| Argentina | 1 | 2008 | 245 | 0.020 |
Why?
|
| Aged | 6 | 2008 | 169143 | 0.020 |
Why?
|
| Urinary Catheterization | 1 | 2007 | 198 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2008 | 345 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 15286 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2004 | 20509 | 0.020 |
Why?
|
| Calibration | 1 | 2008 | 816 | 0.020 |
Why?
|
| Animals | 4 | 2008 | 167960 | 0.010 |
Why?
|
| Neoplasms | 3 | 2008 | 22075 | 0.010 |
Why?
|
| Middle Aged | 5 | 2008 | 220359 | 0.010 |
Why?
|
| Male | 7 | 2008 | 359718 | 0.010 |
Why?
|
| Female | 4 | 2009 | 391246 | 0.010 |
Why?
|
| Morbidity | 1 | 2008 | 1765 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 2004 | 480 | 0.010 |
Why?
|
| Software | 2 | 2008 | 4419 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 2008 | 8055 | 0.010 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2004 | 277 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 2221 | 0.010 |
Why?
|
| Reference Values | 1 | 2008 | 4925 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2005 | 1722 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2005 | 1440 | 0.010 |
Why?
|
| Europe | 1 | 2005 | 3441 | 0.010 |
Why?
|
| United States | 2 | 2022 | 72448 | 0.010 |
Why?
|
| Photons | 1 | 2002 | 581 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2007 | 2821 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8552 | 0.010 |
Why?
|
| Risk | 1 | 2007 | 9632 | 0.010 |
Why?
|
| Massachusetts | 1 | 2008 | 8803 | 0.010 |
Why?
|
| Adult | 3 | 2003 | 220007 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2008 | 64981 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 58980 | 0.000 |
Why?
|
| Time Factors | 1 | 2002 | 40139 | 0.000 |
Why?
|